Clinical Implications of Monitoring ESR1 Mutations by Circulating Tumor DNA in Estrogen Receptor Positive Metastatic Breast Cancer: A Pilot Study
BACKGROUND: ESR1 mutations are frequently detected in ER+ MBC, and have been reported to be associated with endocrine therapy resistance. However, there are little researches to validate whether dynamic monitoring of ESR1 mutations could serve as a predictive plasma biomarker of acquired resistance...
Main Authors: | Xuelu Li, Jiawei Lu, Lanxin Zhang, Yaoting Luo, Zuowei Zhao, Man Li |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2020-02-01
|
Series: | Translational Oncology |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1936523319303948 |
Similar Items
-
Detection of ESR1 Mutations Based on Liquid Biopsy in Estrogen Receptor-Positive Metastatic Breast Cancer: Clinical Impacts and Prospects
by: Hao Liao, et al.
Published: (2020-12-01) -
Clinical value of circulating ESR1 mutations for patients with metastatic breast cancer: a meta-analysis
by: Zhang K, et al.
Published: (2018-08-01) -
ESR1 Gene Mutation in Hormone Receptor-Positive HER2-Negative Metastatic Breast Cancer Patients: Concordance Between Tumor Tissue and Circulating Tumor DNA Analysis
by: Loredana Urso, et al.
Published: (2021-03-01) -
ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer
by: Jamie O. Brett, et al.
Published: (2021-08-01) -
Risk of early progression according to circulating ESR1 mutation, CA-15.3 and cfDNA increases under first-line anti-aromatase treatment in metastatic breast cancer
by: Florian Clatot, et al.
Published: (2020-05-01)